Loading clinical trials...
Loading clinical trials...
An Open-label Repeat Dosing Study of Eltrombopag Olamine (SB-497115-GR) in Adult Subjects, With Chronic Idiopathic Thrombocytopenic Purpura (ITP)
Conditions
Interventions
eltrombopag
Locations
3
Germany
GSK Investigational Site
Hanover, Lower Saxony, Germany
GSK Investigational Site
Berlin, State of Berlin, Germany
GSK Investigational Site
Moscow, Russia
Start Date
March 1, 2007
Primary Completion Date
August 1, 2008
Completion Date
November 1, 2008
Last Updated
July 30, 2013
NCT01072162
NCT00442871
NCT01064336
NCT01098487
Lead Sponsor
GlaxoSmithKline
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions